As of the latest Form 4 filed Jul 1, 2026.
What Aethlon Medical Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Newest filing first — the 10 most recent filings for AEMD.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 2026-06-30 | Shah Chetan Director | FTax | −2.18K | $0.82 | $1.79K | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Gikakis Nicolas Director | FTax | −2.18K | $0.82 | $1.79K | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | BROENNIMAN EDWARD G Director | FTax | −1.09K | $0.82 | $894.62 | No | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Rossetti Angela Director | AAward | +21.8K | $2.29 | $50.0K | No | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Shah Chetan Director | AAward | +21.8K | $2.29 | $50.0K | No | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | Gikakis Nicolas Director | AAward | +21.8K | $2.29 | $50.0K | No | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | BROENNIMAN EDWARD G Director | AAward | +21.8K | $2.29 | $50.0K | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Shah Chetan Director | FTax | −178.00 | $2.19 | $389.82 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | Gikakis Nicolas Director | FTax | −178.00 | $2.19 | $389.82 | No | Form 4 ↗ |
| 2026-04-01 | 2026-03-31 | BROENNIMAN EDWARD G Director | FTax | −89.00 | $2.19 | $194.91 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also AEMD’s full analysis or the market-wide insider trading feed. The tabs above jump to AEMD’s other SEC data.
Source: SEC Form 4 filings for AEMD, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.